Targeted destruction of VISTA boosts anti-tumor immunotherapy
Year: 2025
Type: article
Source: Cell Research
Authors: Li Chen, Xia Bu, Yishuang Sun, Daoyuan Huang, Yong Chen, Tao Hou, Xiaoping Hu, Jingchao Wang, Peiqiang Yan, Yihang Qi, Weiwei Jiang, Yan Xiong, Jing Liu, Yang Gao, Mengxi Huan, Bin Wang, Qianjia Liu, Xiaoming Dai, Fabin Dang, John M. Asara, Masanori Fujimoto, Hiroyuki Inuzuka, Jian Jin, Jinfang Zhang, Gordon J. Freeman, Wenyi Wei
Institutions: Beth Israel Deaconess Medical Center, Harvard University, Dana-Farber Cancer Institute, Wuhan University, Zhongnan Hospital of Wuhan University, Icahn School of Medicine at Mount Sinai, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an Jiaotong University, Nanjing University, Case Comprehensive Cancer Center, Case Western Reserve University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: DF/HCC Kidney Cancer SPORE, G1273380608, G1869449677, G2761064934, G4209434744, Deciphering the physiological role and interplay between ubiquitination and phosphorylation pathways to guide targeted cancer therapies, G7330259265, Elucidating a Novel Mechanism for LATS1/2 in Suppressing Tumorigenesis
OpenAlex ID: W4416162153